Biotech tools · Bioprocess development
Culture Biosciences
A cloud lab that ran other companies’ fermentation for them, now selling the bioreactor itself through Cytiva. Still operating, on its third chief executive since 2024, with the founder off the board since April 2026.
Bioreactors the size of coke cans
In February 2019 TechCrunch described what two Duke graduates had built. Not glass vessels with knobs on the front, but custom robotics, sensors and networks wrapped around vessels that, at 250 milliliters, were “roughly the size of coke cans.”
The company had 50 of them and was building more. Customers shipped in vials of engineered microbes and growth media. Culture thawed them, grew them, sampled them, and pushed every temperature and pH reading into a web application the customer could watch from a laptop.
“We do cloud fermentation.” That was how Will Patrick, the chief executive, put it.
The bottleneck nobody wanted to own
Engineering a microbe to make a molecule is the glamorous half of synthetic biology. The other half is making that microbe behave in a tank, reliably, at a cost that leaves a margin. That needs a room full of fermenters, people to run them, and somebody to read the data.
“What I was noticing was that the problem and the bottleneck in the industry was moving from industrial design to scale-up,” Patrick told TechCrunch. Chemical & Engineering News, which named Culture one of its 10 Start-Ups to Watch in 2020, described the same gap: companies knew how to craft the organism, and stalled on the manufacturing process around it.
Culture’s answer was to rent the room. Customers paid a monthly rate based on how many reactors they used. The company took no royalties. “People really like predictable costs and guaranteed capacity,” Patrick told C&EN.
Two drone engineers
Will Patrick and Matt Ball met at Duke, were roommates, and later worked together on Project Wing, the autonomous delivery drone effort inside Google X. Patrick went on to the MIT Media Lab to research 3D printed microfluidics. Ball had years on sensor and communications hardware at Bay Area startups.
Neither was a biologist. Asked in 2020 how two engineers thought they could build a bioreactor, Ball said: “Will and I are very optimistic people, and we’re deep believers in both the potential of new technology and in our ability to build it.” They drove around San Francisco talking to synthetic biology companies about what hurt, and started the company in 2016.
Three business models in seven years
The first was biomanufacturing-as-a-service for anyone growing cells: fuels, foods, materials, drugs. C&EN reported in 2020 that Culture was running microbes for Zymergen, Clara Foods, Modern Meadow and C16 Biosciences. TechCrunch had earlier named Geltor, Modern Meadow and Pivot Bio.
The second arrived in March 2023, when the company announced it was increasing its focus on upstream bioprocess development of new therapeutics and brought in four executives to do it. By then, it said, “More than 70 client companies” had used the platform. Food and materials were no longer the story. Biologics were.
The third is running now. In April 2025 Culture launched Stratyx 250, described as “the first mobile, cloud-integrated bioreactor” for cell culture process development: a cart of single use 250 mL reactors that sits in the customer’s lab rather than Culture’s. In August 2025 Cytiva, the Danaher bioprocessing arm, became its “exclusive global distributor.” In December 2025 an insider Series C closed to fund it. The April 2026 board release put the strategy in its title: hardware commercialization and SaaS growth.
Leadership churned through the same stretch. Patrick handed the chief executive job to Darcy Birse in April 2024. Birse was gone by autumn: Chris Williams, formerly chief operating officer at Cytek Biosciences, was announced on September 26, 2024, effective October 7. In April 2026 Patrick left the board.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Named customers, reported | TechCrunch, Feb 2019: Geltor, Modern Meadow, Pivot Bio. C&EN, Nov 2020: Zymergen, Clara Foods, Modern Meadow, C16 Biosciences. Clara Foods became The EVERY Company in 2021, and Ginkgo Bioworks completed its acquisition of Zymergen in 2022. | Independent |
| Named customers, company-sourced | Case studies and testimonials name MilliporeSigma, Joyn Bio, Nektar, Sestina Bio, The Every Company, FUJIFILM Biosciences and Virica Biotech. No contract values or run volumes are attached. | Company-stated |
| Installed capacity | 50 reactors in Feb 2019. In Mar 2020 Patrick told MedCity News the company had built 80 in about 10 weeks and would pass 300. The current figure given is “over 22,000 bioreactor runs for more than 100 customers.” No independent count has been published since 2020. | Company-stated |
| The 250 L bioreactors | The Oct 2021 Series B was to “build and scale 5L and 250L cloud bioreactors,” and C&EN reported the same plan. As of Aug 2026 the site lists 250 mL and 5 L only, and says “At the moment, the Stratyx platform only supports 250mL units.” Pilot scale never shipped. | Differs from plan |
| Stratyx 250 performance | 16% lower cost per run, 25% faster development timelines, 30% improved scale-up success, five month payback. All four figures come from the company’s own launch release and white papers. No third party validation has been published. | Company-stated |
| Distribution | Cytiva named exclusive global distributor of Stratyx 250 and its consumables on Aug 6, 2025, with joint development of further formats and scale-up to 2,000 L using Xcellerex X-Platform consumables. Unit numbers not disclosed by either party. | Partner-stated |
| Software partnerships | Google Cloud collaboration, Sep 2024, to put Gemini, BigQuery and Looker behind Console. Ginkgo Technology Network partner since Feb 2024. Xcell Biosciences agreement, Dec 2025, to run Console analytics on AVATAR Foundry systems. | Company-stated |
| Peer-reviewed literature | No PubMed results for the company as of Sep 22, 2026. The technical output is white papers and conference posters, including a NIIMBL national meeting poster in July 2026. | Not found |
Read plainly: the customer list is real and long, and its oldest names came from reporters rather than the company. What has never been published is what an investor would want: how much revenue recurs, how many Stratyx units Cytiva has placed, and whether a 40 person company can carry hardware, a service lab and software at once. The 250 L reactor is the cleanest test of the company’s own forecasting. It was funded in 2021 and does not exist in 2026.
What to watch
- Stratyx unit numbers from Cytiva. An exclusive distribution deal with a Danaher company either produces placements or it does not.
- Whether Nexxys, the in-house bioreactor service, keeps getting investment now that the pitch is hardware and SaaS.
- 5 L support on Stratyx, which the company says is planned but not dated.
- A Series C amount. The December 2025 close was announced without one, and no Form D has been filed.
- Whether the Console AI work becomes a priced product or stays in collaboration announcements.
In their words
“What I was noticing was that the problem and the bottleneck in the industry was moving from industrial design to scale-up.”
Will Patrick, co-founder and then CEO, TechCrunch, 2019 · Independent
“We saw a business opportunity to make it convenient and simple”
Will Patrick, on founding the company, C&EN, 2020 · Independent
“People really like predictable costs and guaranteed capacity.”
Will Patrick, on the subscription model, C&EN, 2020 · Independent
“Will and I are very optimistic people, and we’re deep believers in both the potential of new technology and in our ability to build it.”
Matt Ball, co-founder and CTO, company interview, 2020 · Company
“Culture feels like an extension of our own fermentation lab, not like a CRO.”
Shashway Vajpeyi, fermentation team leader, Modern Meadow, company website · Customer, via company
“The ability to remotely monitor and adjust experiments in real time is streamlining our workflows and improving reproducibility across runs.”
Jondavid De Jong, VP scientific operations, Virica Biotech, in the Stratyx launch release, 2025 · Customer, via company
“By aligning our innovative bioreactor technology with Cytiva’s global reach and leadership in bioprocessing, we are accelerating the future of digital bioprocessing.”
Chris Williams, CEO, Cytiva announcement, August 2025 · Company
Related companies
Sources
- Public recordForm D, Culture Biosciences Inc., CIK 0001804593
- Public recordForm D, E14 SPV Culture Biosciences B LLC, CIK 0001883670
- Public recordEDGAR filing index for Culture Biosciences Inc., all Form D filings
- IndependentTwo former members of Google’s skunkworks division have launched a biomanufacturing company
- IndependentC&EN’s 2020 10 Start-Ups to Watch
- IndependentCulture Biosciences raises $15M in Series A funding round
- IndependentCulture Biosciences raises $80 million
- IndependentCytiva expands collaboration with Culture Biosciences
- IndependentCulture Biosciences opens INTERPHEX 2025 with launch of cloud-integrated mobile bioreactor
- CompanyCulture Biosciences focuses technology and service platform on biologics
- CompanyCulture Biosciences unveils Stratyx 250
- PartnerCytiva and Culture Biosciences expand strategic collaboration
- CompanyCulture Biosciences announces close of Series C round
- CompanyCulture Biosciences announces strategic addition to its board of directors
- CompanyCulture Biosciences appoints Chris Williams as chief executive officer
- CompanyDarcy Birse named CEO of Culture Biosciences
- CompanyCulture Biosciences and Google Cloud announce collaboration
- PartnerXcell Biosciences and Culture Biosciences partner to advance cell therapy quality
- IndependentClara Foods rebrands as The EVERY Company
- CompanyGinkgo Bioworks completes acquisition of Zymergen
- CompanyNexxys, Stratyx and about pages, culturebiosciences.com
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
